Phillip Frost - Mar 8, 2023 Form 4 Insider Report for OPKO HEALTH, INC. (OPK)

Signature
Phillip Frost, M.D., Individually and as Trustee
Stock symbol
OPK
Transactions as of
Mar 8, 2023
Transactions value $
$1,175,384
Form type
4
Date filed
3/9/2023, 05:26 AM
Previous filing
Feb 14, 2023
Next filing
Mar 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPK Common Stock Purchase $336 +300 +0% $1.12 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $43.9K +39K +0.02% $1.13 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $24.9K +22K +0.01% $1.13 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $6.46K +5.7K +0% $1.13 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $122K +107K +0.05% $1.14 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $397K +348K +0.17% $1.14 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $15.5K +13.6K +0.01% $1.15 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $2.18K +1.9K +0% $1.15 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $93.5K +81.3K +0.04% $1.15 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $1.15K +1K +0% $1.15 199M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $68.3K +59.1K +0.03% $1.16 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $24K +20.7K +0.01% $1.16 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $9.75K +7.96K +0% $1.23 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $18.9K +15.4K +0.01% $1.23 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $1.48K +1.2K +0% $1.24 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $14.3K +11.6K +0.01% $1.24 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $14.1K +11.3K +0.01% $1.25 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $115K +92K +0.05% $1.25 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $113K +89.7K +0.04% $1.26 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $3.4K +2.7K +0% $1.26 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $9.29K +7.34K +0% $1.27 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $44.2K +34.8K +0.02% $1.27 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $7.73K +6.04K +0% $1.28 200M Mar 8, 2023 See Footnote F1
transaction OPK Common Stock Purchase $25.8K +20K +0.01% $1.29 200M Mar 8, 2023 See Footnote F1
holding OPK Common Stock 3.07M Mar 8, 2023 Direct
holding OPK Common Stock 30.1M Mar 8, 2023 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.